KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Depreciation: 2020-2022

Historic Accumulated Depreciation for AbCellera Biologics (ABCL) over the last 2 years, with Dec 2022 value amounting to $18.5 million.

  • AbCellera Biologics' Accumulated Depreciation rose 88.02% to $18.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.5 million, marking a year-over-year increase of 88.02%. This contributed to the annual value of $18.5 million for FY2022, which is 88.02% up from last year.
  • Latest data reveals that AbCellera Biologics reported Accumulated Depreciation of $18.5 million as of Q4 2022, which was up 17.40% from $15.7 million recorded in Q3 2022.
  • In the past 5 years, AbCellera Biologics' Accumulated Depreciation registered a high of $18.5 million during Q4 2022, and its lowest value of $5.6 million during Q4 2020.
  • For the 3-year period, AbCellera Biologics' Accumulated Depreciation averaged around $10.7 million, with its median value being $9.8 million (2021).
  • Data for AbCellera Biologics' Accumulated Depreciation shows a peak YoY spiked of 88.02% (in 2022) over the last 5 years.
  • AbCellera Biologics' Accumulated Depreciation (Quarterly) stood at $5.6 million in 2020, then soared by 75.90% to $9.8 million in 2021, then surged by 88.02% to $18.5 million in 2022.
  • Its last three reported values are $18.5 million in Q4 2022, $15.7 million for Q3 2022, and $13.2 million during Q2 2022.